Breaking news on gout
Nuon Therapeutics Announces Positive Topline Results From A Phase 2a Study In Hyperuricemia published
Sun, 20 Jun 2010 01:00:00 PDT
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia...
Gout Drug Benefits Kidney Disease Patients published
Sat, 12 Jun 2010 00:00:00 PDT
A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN)...
BioCryst Initiates A Phase 2 Study Of BCX4208 Alone And In Combination With Allopurinol In Patients With Gout published
Thu, 03 Jun 2010 00:00:00 PDT
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208...
EnzymeRx Announces Strong Phase 1 Results For Pegsitacase published
Sun, 02 May 2010 00:00:00 PDT
April 29, 2010. EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome...
Nuon Therapeutics Identifies Novel Use And Advances NU1618 Into Development For Chronic Hyperuricemia In Patients With Gout published
Thu, 22 Apr 2010 20:00:00 PDT
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010...
COLCRYS(R) (Colchicine, USP) Shows Superior Safety With Comparable Efficacy Compared To High-Dose Colchicine In Treatment Of Early Acute Gout Flares published
Thu, 01 Apr 2010 01:00:00 PDT
A newly-published clinical study demonstrates that Colcrys® (colchicine, USP), a low-dose oral colchicine, is just as effective as high-dose colchicine in reducing pain associated with early acute gout flare, but with a safety profile statistically indistinguishable from placebo. The study, "High vs...
Savient Announces KRYSTEXXA(TM) Resubmitted BLA Accepted For Review By The FDA published
Wed, 31 Mar 2010 01:00:00 PDT
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application (BLA) for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy...
Gout Risk Factors For Women: Obesity, Hypertension, Alcohol And Diuretic Use published
Tue, 30 Mar 2010 04:00:00 PDT
Researchers from Boston University School of Medicine found that women with serum uric acid levels over 5 mg/dl had a significantly lower risk of developing gout than men...
Molecular Prosthesis Against Gout published
Tue, 30 Mar 2010 01:00:00 PDT
Researchers from the ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE) have devised a new method for preventing and permanently eradicating the cause of gout. It involves implanting a biological network that regulates the uric acid levels autonomously. As Paracelsus once stated, the dose makes the poison...
Dual-Energy CT Accurately Diagnoses Gout In Acute, Emergency Settings published
Mon, 22 Mar 2010 02:00:00 PDT
A medical imaging technique called dual-energy computed tomography (CT) is an effective and reliable way to diagnose gout in the acute, emergency setting, according to a study published in the April issue of the American Journal of Roentgenology. Dual-energy CT is an advanced medical imaging technique that can detect vessels and bones and display them in clear contrast to one another...
Launch By Menarini And Ipsen Of ADENURIC(R) (febuxostat) In France For The Treatment Of Chronic Hyperuricemia In Gout published
Sun, 07 Mar 2010 00:00:00 PDT
Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group and Menarini, the first Italian pharmaceutical Group in the world with a significant pan-European presence, announced the launch of ADENURIC® (febuxostat) in France where they will co-promote the drug. Other launches by Menarini are planned shortly, notably in United Kingdom, Germany and Ireland...
Women With Gout At Greater Risk Of Heart Attack Than Men published
Wed, 10 Feb 2010 01:00:00 PDT
Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases. Gout is known to boost the risk of a heart attack in men. But to date, little has been known about the impact of gout on women's cardiovascular health...
Ardea Biosciences Reports Positive Results For RDEA594, Its Lead Product Candidate For Gout, In Combination With Allopurinol Or Febuxostat published
Fri, 08 Jan 2010 02:00:00 PDT
Ardea Biosciences, Inc...
Low-Dose Colchicine (Colcrys) Is Rapid, Effective Treatment For Acute Gout Flares published
Mon, 26 Oct 2009 00:00:00 PDT
PHILADELPHIA - New data show that low-dose colchicine (ColcrysTM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial...
Ardea Biosciences Announces Additional Positive Results From A Phase 2a Study Of RDEA594 At The 2009 ACR/ARHP Annual Scientific Meeting published
Wed, 21 Oct 2009 01:00:00 PDT
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout...
For Management Of Hyperuricemia In Patients With Gout, Uloric (Febuxostat) Demonstrated Efficacy published
Wed, 21 Oct 2009 00:00:00 PDT
Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to A subset of subjects from the CONFIRMS trial who ...
New Data Presented At ACR Meeting Demonstrates Colcrys(TM) (Colchicine, USP) Significantly Reduces Pain Of Acute Gout Flare Within 24 Hours published
Tue, 20 Oct 2009 01:00:00 PDT
URL Pharma, Inc., announced data from a pivotal Phase III study demonstrating that Colcrys(TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares within a 24-hour period as effectively as high-dose colchicine with a side effect profile statistically indistinguishable from placebo...
FDA Approves Colcrys(TM) (colchicine, USP) For Prevention Of Gout Flares published
Tue, 20 Oct 2009 01:00:00 PDT
URL Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on July 30, 2009 for the treatment of acute gout flares when taken at the first sign of a flare...
ULORIC(R) (febuxostat) Demonstrated Efficacy For Management Of Hyperuricemia In Patients With Gout published
Mon, 19 Oct 2009 03:00:00 PDT
Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to A subset of subjects from the CONFIRMS trial who received prior urate-lowering therapy for up to five years achieved sUA According to Michael Becker, M.D...
Rochester-Led Parkinson's Study Pays Off Again, 2 Decades Later published
Tue, 13 Oct 2009 04:00:00 PDT
Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found...
BioCryst Announces Initiation Of Phase 2 Study Of BCX4208 For The Treatment Of Gout published
Tue, 29 Sep 2009 01:00:00 PDT
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects...
EnzymeRx Announces Its IND For Uricase-PEG 20 Becomes Effective published
Mon, 28 Sep 2009 04:00:00 PDT
EnzymeRx, LLC a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective. EnzymeRx filed this IND for intravenous Uricase-PEG 20 in the management of elevated uric acid levels associated with tumor lysis syndrome...
Savient Pharmaceuticals Receives Complete Response Letter From U.S. Food And Drug Administration For KRYSTEXXA(TM) published
Tue, 04 Aug 2009 00:00:00 PDT
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy...
FDA Approves Colchicine For Acute Gout, Mediterranean Fever published
Sun, 02 Aug 2009 00:00:00 PDT
The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder...
Ardea Biosciences Initiates Phase 2b Clinical Trial Of RDEA594, Lead Product Candidate For The Treatment Of Gout published
Wed, 22 Jul 2009 01:00:00 PDT
Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication...
)
|
|
